Most Read

The companies have signed a collaboration agreement for the research, development, manufacturing and commercialisation of up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) to eliminate

AZD1222 was co-invented by Oxford University and its spin-out company Vaccitech. The recombinant adenovirus vaccine, which was licensed by AstraZeneca in May 2020, was tolerated by the participants

The in-human study follows positive pre-clinical results for the treatment candidate, as well as successive approval of the investigational new drug application by the Korean Ministry of Food

Novartis has said that it will provide medicines to governments, NGOs and other institutional customers in up to 79 eligible nations until a vaccine or curative treatment is

Nintedanib already secured approval from the US Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as the first treatment for

Tremfya is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin (IL)-23 and prevents its interaction with the IL-23 receptor, as per Janssen.

The two of the firms’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme, including BNT162b1 and BNT162b2, are being developed to treat SARS-CoV-2. BioNTech chief medical

The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology

More than 20 biopharmaceutical companies have collaborated to establish the AMR Action Fund, which will help focus on medicines that address most resistant bacteria and life-threatening infections. The